Logo image of DWTX

DOGWOOD THERAPEUTICS INC (DWTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DWTX - US92829J2033 - Common Stock

4.07 USD
-0.31 (-7.08%)
Last: 12/26/2025, 8:00:02 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to DWTX. DWTX was compared to 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for DWTX as it has an excellent financial health rating, but there are worries on the profitability. DWTX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year DWTX has reported negative net income.
In the past year DWTX has reported a negative cash flow from operations.
In the past 5 years DWTX always reported negative net income.
In the past 5 years DWTX always reported negative operating cash flow.
DWTX Yearly Net Income VS EBIT VS OCF VS FCFDWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

DWTX has a Return On Assets of -43.46%. This is comparable to the rest of the industry: DWTX outperforms 56.42% of its industry peers.
DWTX's Return On Equity of -51.66% is fine compared to the rest of the industry. DWTX outperforms 65.28% of its industry peers.
Industry RankSector Rank
ROA -43.46%
ROE -51.66%
ROIC N/A
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
DWTX Yearly ROA, ROE, ROICDWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DWTX Yearly Profit, Operating, Gross MarginsDWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

DWTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, DWTX has less shares outstanding
There is no outstanding debt for DWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DWTX Yearly Shares OutstandingDWTX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
DWTX Yearly Total Debt VS Total AssetsDWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 2.36 indicates that DWTX is not a great score, but indicates only limited risk for bankruptcy at the moment.
DWTX has a better Altman-Z score (2.36) than 66.60% of its industry peers.
DWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.36
ROIC/WACCN/A
WACCN/A
DWTX Yearly LT Debt VS Equity VS FCFDWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

DWTX has a Current Ratio of 4.49. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
DWTX's Current ratio of 4.49 is in line compared to the rest of the industry. DWTX outperforms 52.08% of its industry peers.
DWTX has a Quick Ratio of 4.49. This indicates that DWTX is financially healthy and has no problem in meeting its short term obligations.
DWTX has a Quick ratio (4.49) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.49
Quick Ratio 4.49
DWTX Yearly Current Assets VS Current LiabilitesDWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for DWTX have decreased strongly by -209.16% in the last year.
EPS 1Y (TTM)-209.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 17.79% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-58.18%
EPS Next 2Y26.51%
EPS Next 3Y17.79%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DWTX Yearly Revenue VS EstimatesDWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 20M 40M 60M 80M 100M
DWTX Yearly EPS VS EstimatesDWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DWTX Price Earnings VS Forward Price EarningsDWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DWTX Per share dataDWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

DWTX's earnings are expected to grow with 17.79% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.51%
EPS Next 3Y17.79%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DWTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

DOGWOOD THERAPEUTICS INC

NASDAQ:DWTX (12/26/2025, 8:00:02 PM)

4.07

-0.31 (-7.08%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners0.97%
Inst Owner Change-28.53%
Ins Owners0.13%
Ins Owner Change99.03%
Market Cap121.00M
Revenue(TTM)N/A
Net Income(TTM)-39.98M
Analysts82.5
Price Target18.7 (359.46%)
Short Float %0.21%
Short Ratio1.16
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-279.47%
Min EPS beat(2)-556.26%
Max EPS beat(2)-2.68%
EPS beat(4)0
Avg EPS beat(4)-234.65%
Min EPS beat(4)-556.26%
Max EPS beat(4)-2.68%
EPS beat(8)2
Avg EPS beat(8)-127.97%
EPS beat(12)5
Avg EPS beat(12)-75.54%
EPS beat(16)9
Avg EPS beat(16)-50.9%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)7.84%
EPS NQ rev (1m)1.14%
EPS NQ rev (3m)2.52%
EPS NY rev (1m)-89.22%
EPS NY rev (3m)-88.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-20.25
EYN/A
EPS(NY)-4.36
Fwd EYN/A
FCF(TTM)-0.61
FCFYN/A
OCF(TTM)-0.61
OCFYN/A
SpS0
BVpS2.6
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -43.46%
ROE -51.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-95.71%
ROA(5y)-84.23%
ROE(3y)-108.75%
ROE(5y)-94.18%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.49
Quick Ratio 4.49
Altman-Z 2.36
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-209.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-300%
EPS Next Y-58.18%
EPS Next 2Y26.51%
EPS Next 3Y17.79%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-390.07%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-198.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-198.34%
OCF growth 3YN/A
OCF growth 5YN/A

DOGWOOD THERAPEUTICS INC / DWTX FAQ

What is the ChartMill fundamental rating of DOGWOOD THERAPEUTICS INC (DWTX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DWTX.


Can you provide the valuation status for DOGWOOD THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to DOGWOOD THERAPEUTICS INC (DWTX). This can be considered as Overvalued.


What is the profitability of DWTX stock?

DOGWOOD THERAPEUTICS INC (DWTX) has a profitability rating of 1 / 10.


How financially healthy is DOGWOOD THERAPEUTICS INC?

The financial health rating of DOGWOOD THERAPEUTICS INC (DWTX) is 8 / 10.